Becton, Dickinson and Co. | BDX - Equity Capital And Reserves


Becton, Dickinson and Co. reported $24.42B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Agilent USD 7.36B 241M Jun/2026
Align Technology USD 4.23B 83.03M Jun/2026
AngioDynamics USD 176.33M 2.52M Sep/2025
Baxter International USD 6.21B 163M Jun/2026
Becton, Dickinson and Co. USD 24.42B 283M Jun/2026
Bio-Rad Laboratories USD 7.17B 322.6M Jun/2026
Boston Scientific USD 24.93B 934M Jun/2026
Cooper Companies USD 8.33B 89.1M Jun/2026
Danaher USD 52.58B 368M Jun/2026
Dentsply International USD 1.35B 33M Jun/2026
Dexcom USD 2.62B 335.5M Jun/2026
Edwards Lifesciences USD 10.62B 290.5M Jun/2026
Globus Medical USD 4.77B 36.29M Jun/2026
Insulet USD 1.42B 119.6M Jun/2026
Integra LifeSciences USD 1.04B 971K Jun/2026
Intuitive Surgical USD 18.17B 693.9M Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Medtronic USD 50.23B 160M Jun/2026
Solventum Corp USD 4.8B 169M Jun/2026
Stryker USD 22.98B 559M Mar/2026
Tandem Diabetes Care USD 130.39M 2.02M Jun/2026
Teleflex USD 2.9B 179.9M Jun/2026
Terumo JPY 1.66T 77.51B Jun/2026
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
Zimmer Biomet Holdings USD 12.63B 49.1M Jun/2026